



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Christi Kosogof, *et al.*

Serial No.: 10/671,723

Filed: September 26, 2003

For: PYRIMIDINE DERIVATIVES AS
GHRELIN RECEPTOR
MODULATORS

Examiner: (not assigned)

Group Art Unit: 1625

Case No.: 7131.US.01

**CERTIFICATE OF MAILING (37 CFR
1.8 (a))**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents
Mail Stop DD
P. O. Box 1450
Alexandria, VA 22313-1450, on:

Date of Deposit: February 18, 2004


Kathleen Boettcher 2/18/04
Date

TRANSMITTAL LETTER

Commissioner for Patents
Mail Stop DD
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed herewith is an Information Disclosure Statement for Christi Kosogof, *et al.* for PYRIMIDINE DERIVATIVES AS GHRELIN RECEPTOR MODULATORS, the specification of which was filed on September 26, 2003, and received Serial No. 10/671,723.


Also enclosed are: Form PTO 1449 (in duplicate) w/16 references
Return-receipt postcard

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR 1.16, as well as any patent application processing fees under 37 CFR 1.17 associated with this communication for which full payment has not been tendered, to Deposit Account No. 01-0025. A duplicate copy of this sheet is enclosed.

23492

ABBOTT LABORATORIES
Telephone: (847) 936-3362
Facsimile: (847) 938-2623

Respectfully submitted,
Christi Kosogof, *et al.*



Christopher P. Rogers
Registration No. 36,334
Attorney for Applicants



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Christi Kosogof, *et al.*

Serial No.: 10/671,723

Filed: September 26, 2003

For: PYRIMIDINE DERIVATIVES AS
GHRELIN RECEPTOR
MODULATORS

Examiner: (not assigned)

Group Art Unit: 1625

Case No.: 7131.US.01

**CERTIFICATE OF MAILING (37 CFR
1.8 (a))**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents
Mail Stop DD
P. O. Box 1450
Alexandria, VA 22313-1450, on:

Date of Deposit: February 18, 2004

 2/18/04
Kathleen Boettcher Date

TRANSMITTAL LETTER

Commissioner for Patents
Mail Stop DD
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed herewith is an Information Disclosure Statement for Christi Kosogof, *et al.* for PYRIMIDINE DERIVATIVES AS GHRELIN RECEPTOR MODULATORS, the specification of which was filed on September 26, 2003, and received Serial No. 10/671,723.


Also enclosed are: Form PTO 1449 (in duplicate) w/16 references
Return-receipt postcard

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR 1.16, as well as any patent application processing fees under 37 CFR 1.17 associated with this communication for which full payment has not been tendered, to Deposit Account No. 01-0025. A duplicate copy of this sheet is enclosed.

23492

ABBOTT LABORATORIES
Telephone: (847) 936-3362
Facsimile: (847) 938-2623

Respectfully submitted,
Christi Kosogof, *et al.*



Christopher P. Rogers
Registration No. 36,334
Attorney for Applicants



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Christi Kosogof, *et al.*

Serial No.: 10/671,723

Filed: September 26, 2003

For: PYRIMIDINE DERIVATIVES AS
GHRELIN RECEPTOR
MODULATORS

Examiner: (not assigned)

Group Art Unit: 1625

Case No.: 7131.US.01

**CERTIFICATE OF MAILING (37 CFR
1.8 (a))**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents
Mail Stop DD
P. O. Box 1450
Alexandria, VA 22313-1450, on:

Date of Deposit: February 18, 2004


Kathleen Boettcher Date

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Mail Stop DD
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This information disclosure statement is being filed before the mailing date of a first Office Action on the merits under 37 CFR § 1.97(b).

The Applicants submit herewith Form PTO 1449 listing the references cited for this Information Disclosure Statement.


The Applicants respectfully request that the Examiner initial next to each reference listed on the enclosed Form PTO 1449 indicating that the Examiner has considered and made those references of record in this application and that a copy of the initialed Form PTO 1449 be returned to Applicants.

No charge is required for the submission of this Information Disclosure Statement under 37 C.F.R. § 1.97 (b). The Commissioner is hereby authorized to charge any additional filing fees required under 37 C.F.R. § 1.17 concerning this transmission, or to credit any overpayment to Deposit Account No. 01-0025.

23492

ABBOTT LABORATORIES
Telephone: (847) 936-3362
Facsimile: (847) 938-2623

Respectfully submitted,
Christi Kosogof, *et al.*


Christopher P. Rogers
Registration No. 36,334
Attorney for Applicants

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SERIAL NO.

7131.US.01

10/671,723

APPLICANT

Christi Kosogof, et al.

FILING DATE

GROUP

September 26, 2003

1625

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 C.F.R. 1.98 (b))

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE
A1	5 5 2 1 1 9 2	05/28/96	Henrie, II, et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	DOCUMENT NUMBER	PUBLI- CATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO
B1	8 8 0 4 2 9 3	16.06.88	WO			
B2	9 8 3 0 5 5 0	16.07.98	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	Asakawa, A., et al., "Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin", <i>Gastroenterology</i> , 120(2):337-345 (2001)
C2	Asakawa, A., et al., "Antagonism of ghrelin receptor reduces food intake and body weight gain in mice", <i>Gut</i> , 52:947-952 (2003)
C3	Cummings, D.E., et al., "Plasma Ghrelin Levels after Diet-Induced Weight Loss or Gastric Bypass Surgery", <i>The New England Jourm of Med.</i> , 346(21):1623-1630 (2002)
C4	Frohman, L. A. & Jansson, J-O., "Growth Hormone-Releasing Hormone", <i>Endocrine Reviews</i> , 7(3):223-253 (1986)
C5	Howard, A., D., et al., "A receptor in Pituitary and Hypothalamus That Functions in Growth Hormone Release", <i>Science</i> , 273:974-977 (1996)
C6	Kamegai, J., et al., "Central Effect of Ghrelin, an Endogenous Growth Hormone Secretagogue, on Hypothalamic Peptide Gene Expression", <i>Endocrinology</i> , 141(12):4797-4800 (2000)
C7	Kojima, M., et al., "Ghrelin is a growth-hormone-releasing acylated peptide from stomach", <i>letters to nature</i> , 402:656-660 (1999)
C8	Momany, F. A., et al., "Design, Synthesis, and Biological Activity of Peptides which Release Growth Hormone in Vitro", <i>Endocrinology</i> , 108(1):31-39 (1981)
C9	Murakami, N., et al., "Role for central ghrelin in food intake and secretion profile of stomach ghrelin in rats", <i>Journ of Endocrinology</i> , 174:283-288 (2002)
C10	Nakazato, M., et al., "A role for ghrelin in the central regulation of feeding", <i>letters to nature</i> , 409:194-198 (2001)
C11	Shintani, M., et al., "Ghrelin, an Endogenous Growth Hormone Secretagogue, Is a Novel Orexigenic Peptide That Antagonizes Leptin Action Through the Activation of Hypothalamic Neuropeptide Y/Y1 Receptor Pathway", <i>diabetes</i> , 50(2):227-232 (2001)
C12	Shuto, Y., et al., "Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeding, and adiposity", <i>The Journ of Clinical Inves</i> , 109(11):1429-1436 (2002)
C13	Svensson, J., et al., "Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure ¹ ", <i>The Journ of Clin Endocrinology & Metabolism</i> , 83(2):362-369 (1998)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SERIAL NO.

7131.US.01

10/671,723

APPLICANT

Christi Kosogof, et al.

FILING DATE

September 26, 2003

GROUP

1625

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98 (b))

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE
	A1	5 5 2 1 1 9 2	05/28/96	Henrie, II, et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLI- CATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION
	B1	8 8 0 4 2 9 3	16.06.88	WO			YES NO
	B2	9 8 3 0 5 5 0	16.07.98	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	Asakawa, A., et al., "Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin", <i>Gastroenterology</i> , 120 (2):337-345 (2001)
C2	Asakawa, A., et al., "Antagonism of ghrelin receptor reduces food intake and body weight gain in mice", <i>Gut</i> , 52 :947-952 (2003)
C3	Cummings, D.E., et al., "Plasma Ghrelin Levels after Diet-Induced Weight Loss or Gastric Bypass Surgery", <i>The New England Jourm of Med.</i> , 346 (21):1623-1630 (2002)
C4	Frohman, L. A. & Jansson, J-O., "Growth Hormone-Releasing Hormone", <i>Endocrine Reviews</i> , 7 (3):223-253 (1986)
C5	Howard, A., D., et al., "A receptor in Pituitary and Hypothalamus That Functions in Growth Hormone Release", <i>Science</i> , 273 :974-977 (1996)
C6	Kamegai, J., et al., "Central Effect of Ghrelin, an Endogenous Growth Hormone Secretagogue, on Hypothalamic Peptide Gene Expression", <i>Endocrinology</i> , 141 (12):4797-4800 (2000)
C7	Kojima, M., et al., "Ghrelin is a growth-hormone-releasing acylated peptide from stomach", <i>letters to nature</i> , 402 :656-660 (1999)
C8	Momany, F. A., et al., "Design, Synthesis, and Biological Activity of Peptides which Release Growth Hormone in Vitro", <i>Endocrinology</i> , 108 (1):31-39 (1981)
C9	Murakami, N., et al., "Role for central ghrelin in food intake and secretion profile of stomach ghrelin in rats", <i>Journ of Endocrinology</i> , 174 :283-288 (2002)
C10	Nakazato, M., et al., "A role for ghrelin in the central regulation of feeding", <i>letters to nature</i> , 409 :194-198 (2001)
C11	Shintani, M., et al., "Ghrelin, an Endogenous Growth Hormone Secretagogue, Is a Novel Orexigenic Peptide That Antagonizes Leptin Action Through the Activation of Hypothalamic Neuropeptide Y/Y1 Receptor Pathway", <i>diabetes</i> , 50 (2):227-232 (2001)
C12	Shuto, Y., et al., "Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeding, and adiposity", <i>The Jourm of Clinical Inves</i> , 109 (11):1429-1436 (2002)
C13	Svensson, J., et al., "Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure ¹ ", <i>The Jourm of Clin Endocrinology & Metabolism</i> , 83 (2):362-369 (1998)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)